

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

Mouse Anti-Human CD20 Monoclonal Antibody, Alexa Fluor?? 700 Conjugated, Clone 2H7

RRID:AB_1727447

Type: Antibody

Proper Citation

BD Biosciences Cat# 560631, RRID:AB_1727447

Antibody Information

URL: http://antibodyregistry.org/AB_1727447

Proper Citation: BD Biosciences Cat# 560631, RRID:AB_1727447

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Mouse Anti-Human CD20 Monoclonal Antibody, Alexa Fluor?? 700 Conjugated, Clone 2H7

Description: This monoclonal targets CD20

Target Organism: baboon, cynomolgus, rhesus, human

Clone ID: Clone 2H7

Antibody ID: AB_1727447

Vendor: BD Biosciences

Catalog Number: 560631

Record Creation Time: 20250820T053804+0000

Record Last Update: 20250820T220403+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Human CD20 Monoclonal Antibody, Alexa Fluor?? 700 Conjugated, Clone 2H7.

No alerts have been found for Mouse Anti-Human CD20 Monoclonal Antibody, Alexa Fluor?? 700 Conjugated, Clone 2H7.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Young C, et al. (2025) A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune disease. *Immunity*, 58(2), 412.

Lebrec H, et al. (2025) Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease. *iScience*, 28(5), 112447.

Stockmann AP, et al. (2025) DF6215, an ?-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. *Cell reports. Medicine*, 102518.

Albus A, et al. (2024) Protocol for developing *Pseudomonas aeruginosa* type III secretion system-neutralizing monoclonal antibodies from human B cells. *STAR protocols*, 5(4), 103440.

Muik A, et al. (2024) Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1. *Cell reports*, 43(8), 114567.

Simonis A, et al. (2023) Discovery of highly neutralizing human antibodies targeting *Pseudomonas aeruginosa*. *Cell*, 186(23), 5098.

Touizer E, et al. (2023) Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. *iScience*, 26(1), 105862.

Weber T, et al. (2023) Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool. *Science immunology*, 8(89), eadk5845.

Kreer C, et al. (2023) Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals. *Nature communications*, 14(1), 7137.

Asrat S, et al. (2023) TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells. *Cell reports methods*, 3(7), 100522.

Zehner M, et al. (2023) Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer. *Immunity*,

56(11), 2602.

Chandran A, et al. (2022) Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections. *Cell reports. Medicine*, 3(3), 100557.

Vanshylla K, et al. (2022) Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. *Cell host & microbe*, 30(1), 69.

Oyong DA, et al. (2022) Adults with *Plasmodium falciparum* malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children. *EBioMedicine*, 75, 103784.

Ercanoglu MS, et al. (2022) No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults. *iScience*, 25(3), 103951.

Weber T, et al. (2022) Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. *Immunity*, 55(2), 341.

Esaulova E, et al. (2021) The immune landscape in tuberculosis reveals populations linked to disease and latency. *Cell host & microbe*, 29(2), 165.

Kreer C, et al. (2020) Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. *Cell*, 182(4), 843.

Schommers P, et al. (2020) Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. *Cell*, 180(3), 471.

Kreer C, et al. (2020) openPrimeR for multiplex amplification of highly diverse templates. *Journal of immunological methods*, 480, 112752.